2023
Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study
Fu R, Sun K, Wang X, Liu B, Wang T, Morze J, Nawrocki S, An L, Zhang S, Li L, Wang S, Chen R, Sun K, Han B, Lin H, Wang H, Liu D, Wang Y, Li Y, Zhang Q, Mu H, Geng Q, Sun F, Zhao H, Zhang X, Lu L, Mei D, Zeng H, Wei W. Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study. The Lancet Regional Health - Western Pacific 2023, 37: 100799. PMID: 37693879, PMCID: PMC10485681, DOI: 10.1016/j.lanwpc.2023.100799.Peer-Reviewed Original ResearchExcess hazard ratioStage-specific survivalCancer patientsCancer survivalRelative survivalCancer typesIndividual cancersEnd Results (SEER) databasePopulation-based studyFemale breast cancerLung cancer patientsCancer registry dataCancer early detectionMedical SciencesHazard ratioOverall prognosisSurvival disparitiesResults databaseCancer HospitalCancer RegistryCervical cancerPoor prognosisVital statusColorectal cancerCancer careDynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma
Lu L, Risch E, Halaban R, Zhen P, Bacchiocchi A, Risch H. Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. International Immunopharmacology 2023, 118: 110092. PMID: 37004344, DOI: 10.1016/j.intimp.2023.110092.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeSoluble PD-L1 (sPD-L1) levelsPD-L1 ratioPD-L1 levelsSoluble PD-1Soluble PD-L1PD-L1PD-1Patient survivalSurvival statusPD-1/PD-L1Immune checkpoints PD-1T cell exhaustionPatients' survival statusSolid tumor typesInitial immunotherapyCheckpoint blockadeMelanoma patientsPoor prognosisRetrospective studyPatient responseCell exhaustionTumor typesMelanomaSurvival
2022
Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
Han R, Yang H, Ling C, Lu L. Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor. Cancer Cell International 2022, 22: 368. PMID: 36424626, PMCID: PMC9685933, DOI: 10.1186/s12935-022-02786-6.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTNBC cellsBreast cancer treatmentNegative breast cancerCaspase-3 activity analysisExpression levelsSpheroid formation assayFurther RT-PCRTNBC patientsTumor burdenEarly recurrencePoor prognosisAggressive subtypeChemotherapy responseAlternative therapiesPreclinical studiesTNBC progressionMouse modelTherapeutic implicationsPreclinical experimentsSurvival rateTherapeutic useClinic practiceLevel assaysAsparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review
Shen X, Jain A, Aladelokun O, Yan H, Gilbride A, Ferrucci LM, Lu L, Khan SA, Johnson CH. Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review. Frontiers In Molecular Biosciences 2022, 9: 958666. PMID: 36090030, PMCID: PMC9453556, DOI: 10.3389/fmolb.2022.958666.Peer-Reviewed Original ResearchColorectal cancerCRC patientsNarrative reviewSex steroid hormone estrogenFemale CRC patientsAnti-tumor effectsPI3K/Akt/Sex-related influencesSex-related factorsAsparagine synthetase expressionSex-specific factorsClinical outcomesTumor burdenCRC progressionPoor prognosisHormone estrogenEstrogen receptorSOX12 expressionRole of sexTherapeutic useAkt/Cancer cellsSynthetase expressionL-asparaginasePatientsAsparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study
Shen X, Cai Y, Lu L, Huang H, Yan H, Paty PB, Muca E, Ahuja N, Zhang Y, Johnson CH, Khan SA. Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study. Metabolites 2022, 12: 164. PMID: 35208238, PMCID: PMC8875032, DOI: 10.3390/metabo12020164.Peer-Reviewed Original ResearchRecurrence-free survivalOverall survivalColorectal cancer prognosisPoor overall survivalPrimary tumor tissuesTumor metabolomeUnique metabolite profilesCohort studyCRC patientsCRC treatmentFemale patientsPoor prognosisColorectal cancerPrognostic disadvantagePatient outcomesPoor survivalSurgical colectomySex-specific differencesCox proportionalEleven metabolitesUntargeted metabolomics analysisCancer prognosisStage ITumor tissueSignificant sex differences
2018
High tRNA Transferase NSUN2 Gene Expression is Associated with Poor Prognosis in Head and Neck Squamous Carcinoma
Lu L, Zhu G, Zeng H, Xu Q, Holzmann K. High tRNA Transferase NSUN2 Gene Expression is Associated with Poor Prognosis in Head and Neck Squamous Carcinoma. Cancer Investigation 2018, 36: 246-253. PMID: 29775108, DOI: 10.1080/07357907.2018.1466896.Peer-Reviewed Original ResearchConceptsPotential independent prognostic markerShorter overall survivalIndependent prognostic markerHigher mortality riskNeck squamous carcinomaPotential therapeutic targetRandom-effects modelOverall survivalSquamous carcinomaPoor prognosisPrognostic valuePrognostic markerMortality riskTherapeutic targetHNSCCNormal tissuesCell developmentExpressionGene expressionRNA methylationPatientsCarcinomaPrognosisNSUN2Important role
2016
Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer
Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, Canuto EM, Jia W, Katsaros D, Yu H. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecologic Oncology 2016, 143: 642-649. PMID: 27667152, PMCID: PMC5507336, DOI: 10.1016/j.ygyno.2016.09.021.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialHumansMiddle AgedNeoplasm GradingNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingYoung AdultConceptsEpithelial ovarian cancerOvarian cancerStage diseasePatient survivalGrade tumorsASAP1-IT1Survival associationsLong non-coding RNAsCox proportional hazards regression modelPrimary epithelial ovarian cancerProportional hazards regression modelsTumor samplesFresh frozen tumor samplesHigh expressionEarly-stage diseaseFavorable overall survivalLate-stage diseaseHazards regression modelsLow-grade tumorsHigh-grade tumorsOvarian cancer progressionNon-coding RNAsImportant biological actionsOverall survivalPoor prognosis
2014
Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation
Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD, Taylor H, Huang Y. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene 2014, 34: 3076-3084. PMID: 25088204, DOI: 10.1038/onc.2014.236.Peer-Reviewed Original ResearchConceptsTumor cell migrationDNA methylationCell migrationTumor suppressorH19/letPotent tumor suppressorExpression of oncogenesDiverse human cancersMetastasis-promoting genesAnti-diabetic drug metforminLet-7C-MycHuman cancersH19Cell growthNovel mechanismEndometrial cancerPoor prognosisRegulationDrug metforminMethylationTherapeutic opportunitiesSuppressorTumor cellsOncogene
2012
Lin28 regulates HER2 and promotes malignancy through multiple mechanisms
Feng C, Neumeister V, Ma W, Xu J, Lu L, Bordeaux J, Maihle NJ, Rimm DL, Huang Y. Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle 2012, 11: 2486-2494. PMID: 22713243, DOI: 10.4161/cc.20893.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2HER2 expressionLin28 expressionEpidermal growth factor receptor 2Growth factor receptor 2Primary breast tumorsFactor receptor 2Cancer cell growthMajor therapeutic targetMultiple mechanismsAdvanced human malignanciesClinical outcomesPoor prognosisBreast cancerReceptor 2Therapeutic targetBreast tumorsNovel mechanistic insightsHuman malignanciesLin28 overexpressionReceptor tyrosine kinasesCancerCell proliferationHuman cancersPowerful predictor
2011
Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression
Varughese J, Hui P, Lu L, Yu H, Schwartz PE. Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression. Journal Of Oncology 2011, 2011: 628084. PMID: 22187554, PMCID: PMC3236522, DOI: 10.1155/2011/628084.Peer-Reviewed Original ResearchProgression-free survivalClear cell cancerOverall survivalCell cancerUterine cancerAggressive histologic subtypeRetrospective chart reviewSingle institution experiencePlatinum-based chemotherapyAdvanced-stage patientsSingle academic institutionAdjuvant therapyChart reviewFIGO stageWorse survivalUterine corpusClinicopathologic featuresHistologic subtypePoor prognosisTreatment regimensExcellent survivalDisease progressionTreatment strategiesClinicopathologic parametersInnovative therapies
2010
IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.
Qian B, Katsaros D, Lu L, Canuto EM, Benedetto C, Beeghly-Fadiel A, Yu H. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncology Reports 2010, 25: 203-13. PMID: 21109978, PMCID: PMC3075064, DOI: 10.3892/or_00001062.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease-Free SurvivalDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionConceptsInsulin-like growth factor IIEpithelial ovarian cancerOvarian cancerDisease progressionResidual tumor sizeIGF-II peptideFresh tumor samplesIGF-II expressionPromoter-specific expressionIGF-II mRNAGrowth factor IIIGF-II promotersLower mRNA expressionOverall survivalAggressive diseasePoor prognosisTumor sizeDisease characteristicsMethylation-specific PCRTumor gradeTreatment responseIGF-II transcriptionPromoter-specific methylationClinical implicationsCancer